LumiMeds review

The advertised price should be tied to the selected order

LumiMeds currently shows $89 per month for compounded semaglutide and $125 for compounded tirzepatide. The homepage describes provider review, medication, check-ins and delivery as included, without a separate membership fee or dose-related upcharge. These are useful offer details to compare with a care-only membership whose medicine is extra. ^{[1] [2] [3]}

The product pages mention monthly, three-month, six-month and twelve-month options without showing the complete selected invoice. Obtain the term total, debit schedule and renewal date. Payment financing is a separate arrangement; availability of installments does not mean there is no obligation for the remaining term. ^{[2] [3] [4]}

Compare the selected term totals in the complete treatment-cost planner.

For a different medication-and-coaching bundle, compare our MD Exam review.

Cancel-anytime language does not settle the financial exit

The weight-care page says cancel anytime, while linked membership terms describe a fixed-term obligation with no ordinary mid-term cancellation, refund or proration. Those terms also reserve pricing changes after twenty-eight days’ notice despite the price-locked advertising. Establish which agreement applies to the chosen plan rather than select the most reassuring sentence. ^{[1] [4] [9]}

The general terms require portal cancellation before renewal where the applicable plan allows it. They describe a $100 cancellation fee outside medical non-approval and no cancellation once the prescription has been submitted to the pharmacy. The fee does not purchase a right to reverse an order already in fulfillment. ^[5]

Compare commitment and access models in our provider comparisons.

The prescribed product needs to be clearer than the template

The semaglutide page identifies semaglutide and a patient-specific 503A compound, but also contains dual-receptor wording and escalation text inconsistent with that identification. Those portions require direct clarification from the prescriber and dispensing pharmacy; they should not be used as a treatment schedule. The tirzepatide page separately identifies a dual-receptor product. ^{[2] [3]}

The expanded semaglutide identity answer correctly says compounds are not interchangeable with approved branded products. Keep that distinction attached to the actual concentration, supplied amount, storage information and instructions. A familiar ingredient name or a generic safety statement does not complete the assessment. ^[2]

Keep the study products distinct with the semaglutide and tirzepatide trial comparison.

The FDA history concerns advertising, not a current batch verdict

FDA’s September 9, 2025 letter to LumiMeds objected to compounded semaglutide and tirzepatide claims that implied sameness with approved products. It describes the website reviewed in August 2025. The letter is a dated regulatory record, not evidence that an individual current shipment failed testing or a finding about a different product. ^[7]

Current product pages disclose lack of FDA approval, and the identity FAQ draws a clearer brand distinction. That wording should not be treated as proof that FDA has adjudicated every current issue. FDA’s current guidance reserves compounding for patients whose medical needs cannot be met by an approved medicine and highlights dosing and quality risks. ^{[2] [3] [8]}

Consider the clinical response question alongside the evidence on nausea and follow-up.

Reachable care and automatic approval are different propositions

The care FAQ describes asynchronous or live evaluation depending on state rules, followed by continuing care coordination. Product FAQs describe clinician review after the initial treatment period. Neither payment nor a website eligibility estimate guarantees a prescription, a particular dose or an identical refill. ^{[2] [6]}

The portal accepts messages at any time, but the homepage publishes separate response hours: weekdays from 7am to 7pm Pacific and weekends from 8am to 4pm. The shipping FAQ qualifies access by state and the prescribed preparation. Confirm the actual service for your location and the contact available if treatment needs to change. ^{[1] [6]}

Plan continuity with the evidence after treatment stops.

Compare a complete care model before choosing the cheapest headline

The homepage projection uses self-reported results from 6,342 tirzepatide patients and explicitly says it is not a clinical trial. Compensated testimonials are also disclosed. Neither establishes what a new patient will achieve, or the outcome of a different compound. ^[1]

50 Stars Health offers another cash-pay compound comparison; LifeMD is useful when branded-drug access support and ongoing care are the main reasons to join. LumiMeds belongs on the shortlist only after the preparation, clinical contact and selected payment commitment are clear enough to compare fairly. An attractive recurring number is the beginning of that comparison, not its conclusion.

For another bundled compound service, compare our 50 Stars Health review.

For branded-access care, read our LifeMD review.

Understanding the cost

Current advertised flat rates: semaglutide $89/month and tirzepatide $125/month. Monthly, three-, six- and twelve-month options are mentioned; confirm the selected total and debit schedule rather than assuming installments or a cancel-anytime term. Membership conditions reserve pricing changes after notice despite price-lock advertising. ^{[1] [2] [3] [4] [5]}